Capital DailyCapital Daily
Finance

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?

Published July 8, 2026 · Category: Finance

Overview

Invesco Pharmaceuticals ETF (NYSEMKT:PJP) provides exposure to established pharmaceutical companies with lower volatility, while First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) targets high-growth biotech stocks with a slightly lower expense ratio.

Both funds concentrate on the healthcare sector but diverge significantly in their industry focus. The First Trust fund and the Invesco ETF both focus on medical innovation, yet they offer very different risk-and-reward profiles due to their specific industry concentrations and historical price volatility.

Details

Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.